Second Genome Stock

Second Genome offers a pipeline of microbiome modulators that impact infection, immunity and metabolic diseases.

Sign up today and learn more about Second Genome Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors

Advanced Technology Ventures


San Francisco CA, US

Total Funding


About Second Genome Stock

Second Genome, a venture-backed Bay Area based life sciences company, is committed to improving the quality of human health through microbiome-based personalized medicine. Founded in 2009 by leading experts in microbial research, molecular diagnostics, and biotechnology R&D, Second Genome is using its proprietary Microbiome Signature Discovery platform to generate novel insights relating the microbiome with a wide range of human health disorders. Working with academic and commercial collaborators, Second Genome is developing novel diagnostic tools and therapies for unmet needs in gastrointestinal disorders. The company has established a pipeline of microbiome modulators that impact infection, inflammation, and metabolic diseases. Second Genome entered into the first ever big pharmaceutical partnership focused on microbiome drug discovery with Janssen Biotech, Inc. in June 2013 for new treatments for ulcerative colitis.


Advanced Technology Ventures

Actifio, Host Analytics, Second Genome

Funding History

August 2011$5.0M
June 2013$6.5M
April 2016$43.0M
July 2016$8.4M


Chief Scientific Officer

Karim Dabbagh

Co-Founder & SVP, Platform Technologies

Janet A. Warrington

Senior Director, Corporate Development

Nadir Mahmood

Bioinformatics Scientist

Cheryl-Emiliane Chow

SVP Corporate Development

Mohan Iyer

CEO & President

Glenn Nedwin

Co-Founder & Head of Bioinformatics

Todd DeSantis

Sr VP Research & Development

Peter S. DiStefano


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: